<DOC>
	<DOCNO>NCT00003961</DOCNO>
	<brief_summary>RATIONALE : Colony-stimulating factor , sargramostim , may increase number immune cell find bone marrow peripheral blood . PURPOSE : Phase II trial study effectiveness sargramostim bone marrow transplantation treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Sargramostim After Bone Marrow Transplantation Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect sargramostim ( GM-CSF ) progression-free 1-year survival patient myelodysplastic syndrome undergone T-cell-depleted CD34+ augment allogeneic bone marrow transplantation . OUTLINE : All patient receive elutriated , CD34+ stem cell augment donor bone marrow accord another protocol day 0 . Patients receive sargramostim ( GM-CSF ) subcutaneously day 5-60 . Patients follow day 120 , 180 , 360 periodically thereafter . PROJECTED ACCRUAL : A total 45 patient accrue study within 3-4 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically proven myelodysplastic syndrome ( MDS ) one follow type : Refractory anemia excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia MDS multiple chromosomal abnormality MDS life threaten cytopenia least 2 cell line Platelet count &lt; 30,000/mm^3 OR Absolute neutrophil count great 1,000/mm^3 OR Anemia require transfusion support Leukemia MDS ( meet requirement , great 30 % blast marrow ) No acute leukemia Medically eligible bone marrow transplant accord standard operating procedure Sidney Kimmel Cancer Center Johns Hopkins Blood Bone Marrow Transplant PATIENT CHARACTERISTICS : Age : 18 65 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify Other : No prior acute allergic reaction sargramostim ( GMCSF ) Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
</DOC>